Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREPAMIR gene therapy study in severe sickle cell disease
2025-521257-17-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2026
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of DREAM01 and imatinib in sickle cell disease (SCD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Efficacy and safety after intravenous infusion of DREAM01 gene therapy with or without prior imatinib treatment. Planned start Feb 2026; status: authorised.
02
Drugs
DREAM01imatinib
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2025-521257-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521257-17-00.